Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Verschuuren

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
The Lancet. Neurology|June 19, 2021
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialJames F Howard, Vera Bril, Tuan Vu, et al.
European Journal of Neurology|January 24, 2023
Reply to the Letter to the Editor in response to "Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal"Andreas Meisel, Fulvio Baggi, Anthony Behin, et al.
Neurology|November 4, 2020
International Consensus Guidance for Management of Myasthenia Gravis: 2020 UpdatePushpa Narayanaswami, Donald B Sanders, Gil Wolfe, et al.
Neuromuscular Disorders : NMD|October 14, 2014
Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophyStephen Lynn, Annemieke Aartsma-Rus, Kate Bushby, et al.
Neurology|July 1, 2016
International consensus guidance for management of myasthenia gravis: Executive summaryDonald B Sanders, Gil I Wolfe, Michael Benatar, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 4, 2020
Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effectsJon Landa, Mar Guasp, Mar Petit-Pedrol, et al.
Frontiers in Neurology|February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravisJames F Howard, Vera Bril, Tuan Vu, et al.
Neuromuscular Disorders : NMD|April 10, 2023
Outcomes after robotic thymectomy in nonthymomatous versus thymomatous patients with acetylcholine-receptor-antibody-associated myasthenia gravisFlorit Marcuse, Janneke G J Hoeijmakers, Monique Hochstenbag, et al.
Orphanet Journal of Rare Diseases|March 12, 2025
Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable dataAbderhmane Slioui, Giulia Tammam, Fiammetta Vanoli, et al.
Journal of Autoimmunity|December 15, 2016
IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patientsInga Koneczny, Jo A A Stevens, Anna De Rosa, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
The Lancet. Neurology|June 19, 2021
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialJames F Howard, Vera Bril, Tuan Vu, et al.
European Journal of Neurology|January 24, 2023
Reply to the Letter to the Editor in response to "Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal"Andreas Meisel, Fulvio Baggi, Anthony Behin, et al.
Neurology|November 4, 2020
International Consensus Guidance for Management of Myasthenia Gravis: 2020 UpdatePushpa Narayanaswami, Donald B Sanders, Gil Wolfe, et al.
Neuromuscular Disorders : NMD|October 14, 2014
Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophyStephen Lynn, Annemieke Aartsma-Rus, Kate Bushby, et al.
Neurology|July 1, 2016
International consensus guidance for management of myasthenia gravis: Executive summaryDonald B Sanders, Gil I Wolfe, Michael Benatar, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 4, 2020
Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effectsJon Landa, Mar Guasp, Mar Petit-Pedrol, et al.
Frontiers in Neurology|February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravisJames F Howard, Vera Bril, Tuan Vu, et al.
Neuromuscular Disorders : NMD|April 10, 2023
Outcomes after robotic thymectomy in nonthymomatous versus thymomatous patients with acetylcholine-receptor-antibody-associated myasthenia gravisFlorit Marcuse, Janneke G J Hoeijmakers, Monique Hochstenbag, et al.
Orphanet Journal of Rare Diseases|March 12, 2025
Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable dataAbderhmane Slioui, Giulia Tammam, Fiammetta Vanoli, et al.
Journal of Autoimmunity|December 15, 2016
IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patientsInga Koneczny, Jo A A Stevens, Anna De Rosa, et al.
Pageof 3